Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …

Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy
historically have poor outcomes. Approximately 12–15% of older patients with AML harbor …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the proliferation and aberrant differentiation of immature clonal myeloid cells. The …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Background In recent years, the literature associated with healthcare big data has grown
rapidly, but few studies have used bibliometrics and a visualization approach to conduct …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute
myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a …

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients
and is associated with poor overall survival (OS). We analyze the characteristics, treatment …